Variable platelet responsiveness to aspirin and clopidogrel: role of platelet function and genetic polymorphism testing

Translational Research

Volumn 154, Issue 6, 2009, Pages 309-313

  Azam, Salman M ^a   Jozic, Joseph ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; CANGRELOR; CLOPIDOGREL; CYCLOOXYGENASE 1; CYTOCHROME P450 2C19; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PRASUGREL; PROTON PUMP INHIBITOR; SCH 530348; TICAGRELOR; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; BLEEDING; BLOOD EXAMINATION; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; DNA POLYMORPHISM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; FLOW CYTOMETRY; GASTROINTESTINAL HEMORRHAGE; GENETIC POLYMORPHISM; HEALTH CARE COST; HUMAN; LIGHT TRANSMITTANCE AGGREGOMETRY; LOADING DRUG DOSE; PATIENT COMPLIANCE; PERCUTANEOUS CORONARY INTERVENTION; POINT OF CARE TESTING; POSTOPERATIVE THROMBOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

EID: 70449505105     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2009.09.011     Document Type: Review

References (39)

1. Roth G.J., and Majerus P.W. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 56 (1975) 624-632
2. [No authors listed]. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 2 (1988) 349-360
3. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
4. Patrono C., Coller B., FitzGerald G.A., Hirsh J., and Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (2004) 234S-264S
5. [No authors listed]. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348 (1996) 1329-1339
6. Steinhubl S.R., Berger P.B., Mann III J.T., et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 (2002) 2411-2420
7. Chen Z.M., Jiang L.X., Chen Y.P., et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366 (2005) 1607-1621
8. Sabatine M.S., Cannon C.P., Gibson C.M., Lopez-Sendon J.L., Montalescot G., Theroux P., et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352 (2005) 1179-1189
9. Grotemeyer K.H., Scharafinski H.W., and Husstedt I.W. Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients. Thromb Res 71 (1993) 397-403
10. Mueller M.R., Salat A., Stangl P., et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 78 (1997) 1003-1007
11. Chen W.H., Lee P.Y., Ng W., Tse H.F., and Lau C.P. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J Am Coll Cardiol 43 (2004) 1122-1126
12. Hankey G.J., and Eikelboom J.W. Aspirin resistance. Lancet 367 (2006) 606-617
13. Ajzenberg N., Aubry P., Huisse M.G., et al. Enhanced shear-induced platelet aggregation in patients who experience subacute stent thrombosis: a case-control study. J Am Coll Cardiol 45 (2005) 1753-1756
14. Gurbel P.A., Bliden K.P., Samara W., et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 46 (2005) 1827-1832
15. Snoep J.D., Hovens M.M., Eikenboom J.C., van der Bom J.G., and Huisman M.V. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 167 (2007) 1593-1599
16. Clopidogrel. Bridgewater, NJ: Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership. Revised May 2009.
17. Smith Jr. S.C., Feldman T.E., Hirshfeld Jr. J.W., et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 113 (2006) e166-e286
18. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 49 (2007) 1505-1516
19. Michelson A.D., Frelinger III A.L., and Furman M.I. Current options in platelet function testing. Am J Cardiol 98 (2006) 4N-10N
20. Smith J.W., Steinhubl S.R., Lincoff A.M., et al. Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation 9 99 (1999) 620-625
21. Jilma B., and Fuchs I. Detecting aspirin resistance with the platelet function analyzer (PFA-100). Am J Cardiol 88 (2001) 1348-1349
22. Harrison P., Segal H., Silver L., Syed A., Cuthbertson F.C., and Rothwell P.M. Lack of reproducibility of assessment of aspirin responsiveness by optical aggregometry and two platelet function tests. Platelets 19 (2008) 119-124
23. Patrono C., Ciabattoni G., Patrignani P., et al. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 72 (1985) 1177-1184
24. Montalescot G., Drobinski G., Maclouf J., et al. Evaluation of thromboxane production and complement activation during myocardial ischemia in patients with angina pectoris. Circulation 84 (1991) 2054-2062
25. Steinhubl S.R., Bhatt D.L., Brennan D.M., Montalescot, et al. Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann Intern Med 150 (2009) 379-386
26. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., et al. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J 25 (2004) 1903-1910
27. Patti G., Colonna G., Pasceri V., Pepe L.L., Montinaro A., and Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2) study. Circulation 111 (2005) 2099-2106
28. von Beckerath N., Kastrati A., Wieczorek A., et al. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J 28 (2007) 1814-1819
29. Angiolillo D.J., Shoemaker S.B., Desai B., et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 115 (2007) 708-716
30. Pettersen A.A., Seljeflot I., Abdelnoor M., and Arnesen H. Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design. Scand Cardiovasc J 38 (2004) 353-356
31. Price M.J., Berger P.B., Angiolillo D.J., et al. Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: design and rationale of the GRAVITAS trial. Am Heart J 157 (2009) 818-824 e1
32. Mehta S.R., Bassand J.P., Chrolavicius S., et al. Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. Am Heart J 156 (2008) 1080-1088 e1
33. Wiviott S.D., Braunwald E., McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357 (2007) 2001-2015
34. Marin F., Gonzalez-Conejero R., Capranzano P., Bass T.A., Roldan V., and Angiolillo D.J. Pharmacogenetics in cardiovascular antithrombotic therapy. J Am Coll Cardiol 54 (2009) 1041-1057
35. Mega J.L., Close S.L., Wiviott S.D., et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360 (2009) 354-362
36. Pereira N.L., and Weinshilboum R.M. Cardiovascular pharmacogenomics and individualized drug therapy. Nat Rev Cardiol 6 (2009) 632-638
37. Collet J.P., Hulot J.S., Pena A., et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373 (2009) 309-317
38. Hulot J.S., and Fuster V. Antiplatelet therapy: personalized medicine for clopidogrel resistance?. Nat Rev Cardiol 6 (2009) 334-336
39. Fontana P., Dupont A., Gandrille S., et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 108 (2003) 989-995